Form 4: Cara Therapeutics Director Vogelbaum Receives Stock Options and Restricted Stock Units

Director Martin Vogelbaum acquired stock options and restricted stock units in Cara Therapeutics, according to a recent SEC filing.

Summary

• On June 4, 2024, Martin Vogelbaum, a director of Cara Therapeutics, Inc., was granted 301,295 restricted stock units (RSUs) and an option to purchase 390,000 shares of common stock.
• The RSUs represent the contingent right to receive one share of common stock each.
• The RSUs and options vest on the earlier of June 4, 2025, or immediately prior to the Issuer's next annual meeting of stockholders following the grant date, contingent upon continued service as a director.
• The exercise price of the stock option is $0.664.
• Following these transactions, Vogelbaum beneficially owns 411,007 shares of common stock and options for 390,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of equity to a director is a standard practice and aligns interests with shareholders. There are no explicit negative implications.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

Grants of stock options and restricted stock units are common practices in the pharmaceutical industry to incentivize and retain key personnel, including directors.

Comparison to Industry Standards

• Director compensation packages, including stock options and RSUs, are common in publicly traded biotech companies like Cara Therapeutics.
• The size and vesting schedules of these grants are typically benchmarked against peer companies to ensure competitiveness and alignment with shareholder interests.
• Companies such as Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation strategies for their directors.

Stakeholder Impact

• The grant of equity to a director can positively impact shareholders by aligning management's interests with theirs.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates